表紙
市場調查報告書
商品編碼
704963

全球製酸藥市場:各醫藥品分類、劑型、通路、地區(2018年∼2023年)

Antacids Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球製酸藥市場,預計從2018年到2023年的整個預測期內以約4.3%的年複合成長率發展。

本報告提供全球製酸藥市場調查,市場概要,各醫藥品分類、劑型、通路、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題(DROC)

  • 成長要素
    • 苦於胃食道逆流症(GERD)的老年人增加
    • 由於生活方式的變化造成的胃酸分泌量的增加
    • 非類固醇消炎劑等醫藥品的副作用
  • 阻礙因素
    • 不關心胃酸過多症的症狀
    • 如胃酸的二次分泌的制酸藥的副作用
    • 替代藥品的增加
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各醫藥品分類
    • 質子幫浦阻斷劑
    • 組織胺H2受體拮抗劑
    • 酸中和劑
  • 各劑型
    • 錠劑
    • 液劑
    • 散藥
  • 各銷售管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 市場主要企業

  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble
  • Reckitt Benckiser Group PLC
  • Sanofi
  • Sun Pharmaceuticals Ltd
  • 武田藥品工業
  • Valeant Pharmaceuticals International, Inc.

第10章 市場未來展望

目錄
Product Code: 62826

The antacids market is expected to register a CAGR of 3.7% over the forecast period.

The COVID-19 pandemic is expected to have a significant impact on the Antacids market. According to the research article published in the American Journal of Gastroenterology, 2020, a retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020, was conducted to compare outcomes in patients hospitalized with coronavirus receiving famotidine therapy with those not receiving famotidine. The results from the study revealed that the use of Famotidine (which is used in treating symptoms of acid reflux and heartburn), in hospitalized COVID-19 patients was found to be associated with a lower risk of mortality, lower risk of the combined outcome of mortality, and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19. Hence, the increasing studies related to the use of antacids in treating COVID-19 are expected to impact the studied market growth over the forecast period.

The propelling factors for the growth of the antacids market include the growing geriatric population suffering from Gastroesophageal Reflux Disease (GERD), poor lifestyle choices leading to higher incidences of acidity, and side effects of drugs like non-steroidal, anti-inflammatory drugs.

According to a United Nations World Ageing 2019 report, in 2019, there were around 703 million people aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019, and 65% of the geriatric population has to deal with acid reflux. This acts as one of the major factors boosting the antacid market globally. There has been an increase in the geriatric population and this is one of the most favorable growth factors for the antacids market as the demographic is highly vulnerable to peptic ulcers and gastroesophageal reflux disorders.

In the elderly population, the acidic complications recurrent infrequently, which makes it a unique challenge for both the primary care provider and the gastroenterologist. In addition, such patients often suffer from several symptomatic disorders, such as erosive esophagitis, Barrett esophagus, and esophageal cancer, in which a combination of therapies are used for the treatment and the use of antacids significantly rises in such cases.

In addition, there is also growth in e-commerce that is likely to augment the demand for antacids through online retailing channels over the next few years. Therefore, the rising popularity of e-commerce and surge in the number of online medicine providers are expected to positively impact the market's overall growth. However, the growing number of alternatives available in the market to antacids and the ignorance of people towards the symptoms of acidity is expected to have a negative impact on the market growth.

Key Market Trends

The Tablet Sub-Segment, by Formulation Type, is Expected to be the Major Contributor to the Market Over the Forecast Year

The presence of a variety of chewable tablets in the market with different flavors that help to improve patient adherence to the medication is expected to contribute to the growth of the segment. Tablets also provide the correct amount of dosage to the patients and they are easy to store. These factors can be attributed to the segment growth over the forecast period. Tablets are the most widely used solid dosage forms as it is the cheapest oral dosage form, and easy to handle, use and carry. Additionally, the growing geriatric population is expected to drive the market growth as the elderly population is more prone to gastrointestinal disorders. According to the data from the World Population Prospects, 2019 revision, by 2050, one in six people in the world may be over the age of 65 years (16%), an increase from one in 11 in 2019 (9%), globally. Furthermore, the major market players are focusing on Research and Development activities, to bring new and reliable products to the market, and are also focusing on product launches.​ For instance, in January 2019, Dr Reddy's laboratories launched generic omeprazole delayed-release tablets for the treatment of heartburn in the United States. Also, In April 2018, Perrigo launched a new, orally disintegrating omeprazole tablet for the treatment of frequent heartburn. Thus, owing to the above-mentioned factors, the market studied is expected to grow significantly.

North America Holds the Major market and is Expected to Follow a Similar Trend over the Forecast Period

The North American Antacids market is expected to grow significantly due to the growing geriatric population and lifestyle changes leading to gastrointestinal problems among the American population. Also, the growing trend toward self-medication in North American countries such as the United States is increasing the demand for over-the-counter digestive products, such as antacids. Antacids are the most common over-the-counter products purchased in the United States. Some of the antacid brands in the country include Nexium 24 hour, Prilosec OTC, Zantac 150, and Tums. According to the study published in the American Journal of Gastroenterology, in 2018, out of 71,812 individuals who participated in the survey, 61% reported having more than one Gastrointestinal symptom in the given week. The most reported symptom is heartburn/reflux. Similarly, according to the Centers for Disease Control and Prevention (CDC) 2018 statistics, the total number of adults diagnosed with ulcers in the United States found to be 14.8 million. The number of population with ulcers is proportional to the population suffering from GERD. Additionally, according to the research article published in StatPearls, 2021, GERD is one of the most common gastrointestinal disorders, with a prevalence of approximately 20% of adults in western countries and the estimated prevalence of GERD in the United States was between 18.1% to 27.8%. Thus, owing to the high prevalence of gastrointestinal disorders and increasing awareness of Over-the-Counter antacids for self-medication among the American population is expected to help in the significant growth of the studied market in the region over the forecast period.

Competitive Landscape

The Antacids market is moderately competitive and the overall market faces intense competition over the forecast period due to the presence of multinational players and small to medium-sized companies entering into the market. The major players of the studied market are Johnson and Johnson, GlaxoSmithKline plc, Sanofi S.A., Bayer AG, and Sun Pharmaceuticals Ltd among others. The key players have adopted strategies such as strategic acquisitions, collaborations, and partnerships, that will help them expand their geographical presence and will strengthen their business position as well.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Geriatric Population Suffering from Gastroesophageal Reflux Disease (GERD)
    • 4.2.2 Poor Lifestyle Choices Leading to Higher Incidences of Acidity
    • 4.2.3 Side Effects of Drugs like Non-Steroidal Anti-Inflammatory Drugs
  • 4.3 Market Restraints
    • 4.3.1 Ignorance of People towards Symptoms of Acidity
    • 4.3.2 Side Effects Related to Antacids like Acid Rebound
    • 4.3.3 Growing Number of Alternatives in the Market for Antacids
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Formulation Type
    • 5.1.1 Tablet
    • 5.1.2 Powder
    • 5.1.3 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 E-Commerce
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Sun Pharmaceuticals Ltd
    • 6.1.5 Sanofi S.A
    • 6.1.6 WellSpring Pharmaceutical Corporation
    • 6.1.7 Advance Pharmaceutical Inc.
    • 6.1.8 CVS Pharmacy
    • 6.1.9 Safetec of America, Inc.
    • 6.1.10 Pfizer inc.
    • 6.1.11 Boehringer Ingelheim International GmbH
    • 6.1.12 Dr. Reddy's Laboratories Ltd.
    • 6.1.13 Reckitt Benckiser Group plc.
    • 6.1.14 Takeda Pharmaceutical Company Limited
    • 6.1.15 Procter & Gamble

7 MARKET OPPORTUNITIES AND FUTURE TRENDS